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Substance use is a significant public health problem in the United
States. National statistics show that in 2015, over 139 million U.S. resi-
dents ages 12 and older reported drinking alcohol in the past month
and nearly half of them (67 million) engaged in binge drinking; 64 mil-
lion Americans consumed tobacco products, predominantly cigarettes;
and 27 million Americans used some type of illicit drug, including non-
medical use of prescription drugs [1]. Nationally, consumption of some
substances (e.g., tobacco, alcohol, and cocaine) decreased over the past
10 years, while use of other drugs (e.g., marijuana, heroin, and pre-
scription pain relievers) has become increasingly more prevalent [1].
Substance use in Indiana has mirrored national trends to some extent;
however, the state also has its own unique set of challenges. Indiana
counted 1,245 fatal drug overdoses in 2015, representing an age-adjust-
ed mortality rate of 19.5 deaths per 100,000 Hoosiers, placing the state
17th in the nation for drug overdose fatalities [2]. Furthermore, Indiana
ranks among the states with the highest rates of tobacco use [3].
Tobacco use among expectant mothers is of particular concern, as near-
ly 15% of Hoosier women smoke during pregnancy [4].
Excessive use of alcohol and drugs has been linked to increased mor-
bidity and mortality from cardiovascular conditions; injuries and motor
vehicle crashes; sexually transmitted and blood-borne illnesses, includ-
ing HIV/AIDS and hepatitis B and C, resulting from risky sexual behav-
iors and/or injection drug use; pregnancy complications and neonatal
abstinence syndrome (NAS); and drug overdoses [5, 6]. Additionally,
substance use can lead to harmful social and legal consequences, such
as family disruptions, financial problems, lost productivity, failure in
school or at work, domestic violence, child abuse, and crime [5]. The
National Institute of Drug Abuse (NIDA) estimates that the total cost
of substance abuse in the nation, including costs related to lost produc-
tivity, health, and crime, exceed $700 billion annually [7]. 
Most Commonly Abused Substances  
The mind-altering substances most frequently abused include alco-
hol, tobacco (nicotine), marijuana, opioids (prescription pain relievers
and heroin), cocaine, and methamphetamine. 
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SUMMARY
Over the past 10 years
•    Alcohol and tobacco continue to be the most widely used
substances.
•    Indiana’s high smoking prevalence, particularly among
expectant mothers, led the state to identify tobacco as one of
its substance abuse prevention priorities.
•    The opioid epidemic involving both prescription pain reliev-
ers and heroin has impacted Indiana tremendously, leading
to significant increases in addiction treatment admissions
and overdose deaths attributable to these drugs.
•    The economic impact of substance abuse is considerable. In
Indiana, the estimated annual costs attributable to tobacco
use were approximately $6.8 billion; alcohol consumption
exceeded $4.4 billion; and overdose deaths accrued to $1.4
billion.
•    Policy recommendations to address substance abuse include
o Expanding access to treatment, especially MAT  programs
o Incorporating a recovery-based framework
o Promoting the use of naloxone
o Preventing transmission of HIV and hepatitis C among
injection drug users
o Implementing effective youth prevention programs
o Monitoring substance abuse in the state
2Alcohol is the most commonly used and abused substance through-
out the United States and excessive consumption can affect the health
and wellbeing of those using it [8]. Alcohol is a central nervous sys-
tem depressant and can impact an individual in as little as 10 min-
utes. In small amounts, alcohol is typically not a health concern, but
regular and excessive consumption can have immediate and long-
term effects. Short-term effects of alcohol include mood changes,
impaired coordination, and slurred speech. In large amounts, alcohol
consumption can cause breathing problems, coma, or death [8].
Regular consumption for long periods of time can impact liver, pan-
creas, and heart health as well as increase the risk for certain types of
cancer [9]. In addition to affecting users, alcohol can also affect those
around them through violence, alcohol-related driving accidents, and
risks to an unborn infant [8]. The effects of alcohol may vary depend-
ing on the individual’s age, family history of alcohol use, and the fre-
quency of consumption [8].
Tobacco comes in a variety of forms and can be smoked, chewed, or
sniffed. Though cigarettes continue to be the most widely used tobac-
co product in the nation, electronic cigarettes (e-cigarettes) have
become more and more popular, especially among youth. Tobacco
contains nicotine, a highly addictive substance that causes the body to
release epinephrine (adrenaline). Epinephrine has a stimulating effect
on the central nervous system, raising blood pressure, respiration,
and heart rate. Smoking has long-lasting extensive health impacts,
often leading to lung disease, including chronic bronchitis, emphyse-
ma, and lung cancer, but has also been linked to several types of can-
cer. Individuals who smoke are at an increased risk for heart disease,
which can lead to heart attack and stroke. [10]. In the United States,
tobacco is responsible for more than 480,000 preventable deaths
annually [11]. People exposed to secondhand smoke, i.e., the smoke
produced from lit tobacco products and exhaled by a smoker, are at
increased risk for lung cancer, heart disease, and respiratory infections
as well. A particularly vulnerable population is infants born to women
who smoked during pregnancy. Smoking during pregnancy increases
the risk of stillbirth as well as pre-term delivery and low neonatal
birth weight, both of which can adversely affect a child’s health later
in life [12]. 
Marijuana is derived from the Cannabis sativa plant. Its main psy-
choactive compound is delta-9-tetrahydrocannabinol (THC) [13].
Marijuana can be inhaled or ingested, frequently causing the user to
experience an altered state of mind, distorted sense of time, mood
changes, impaired body movement, hallucinations, paranoia, and
impaired memory shortly after consumption. Long-term impacts of
marijuana use include breathing problems, poorer physical and men-
tal health, and among individuals who regularly used marijuana in
their teenage years, decreases in IQ in early adulthood [13]. Some
studies suggest a connection between marijuana use and depression
and anxiety in teens [14-16], though results are mixed [17, 18]. As of
2016, 28 states have legalized marijuana for medical use [19] and
eight for recreational use [20]. With the increasing public support for
marijuana, it has become the most widely used illicit substance in the
country with 22.2 million current users [1].
Prescription opioids (pain relievers) are pharmaceutical drugs that
are typically prescribed by a healthcare professional to treat acute or
chronic pain conditions. Opioids bind to specific opioid receptors in
the body, generating pain relief and often, especially in higher doses,
a feeling of euphoria [21]. Due to the addictive nature of these drugs,
prescription opioids are frequently misused. The majority of individu-
als using prescription opioids for nonmedical purposes receive them
from a friend or relative [22]. Prescription pain relievers have similar
characteristics and effects as heroin and there is evidence that any
opioid use is a risk factor for future heroin use; though only a subset
of those misusing prescription drugs follow this course [23].
Substance use disorders related to prescription opioids affected 1.9
million Americans age 12 and over in 2014 [1]. 
Heroin is a highly addictive semi-synthetic opioid made from the
resin of the opium poppy. The drug can be injected, inhaled, or
smoked. Once heroin enters the brain, it is converted into morphine,
which rapidly binds to opioid receptors, leading to euphoria [24].
Because both heroin and prescription pain relievers are opioid-based
substances, they share many chemical properties and physical effects.
While some research shows that prescription drug users may be at
higher risk of future heroin use, only a subset of those having used
prescription drugs progress to heroin [23]. Heroin use may result in a
variety of serious health conditions. Repeated or chronic use can lead
to addiction, increased risk for infectious diseases including
HIV/AIDS and hepatitis C, and drug overdoses. Maternal heroin use
during pregnancy may cause low birth weight in babies and can lead
to NAS [24]. The recent national increase in heroin use has been
attributed, at least in part, to heroin becoming increasingly available
at a low cost [23]. According to the CDC, the level of use of prescrip-
tion and non-prescription opioids across the country has reached epi-
demic proportions. 
Cocaine is a highly addictive stimulant derived from the South
American coca plant and is generally snorted or injected. Crack is a
form of cocaine made by crystallizing cocaine. Crack gets its name
from the crackling sounds which result when crystals are heated,
allowing their vapors to be inhaled [25]. When consumed, cocaine
causes the brain to release dopamine, a neurotransmitter responsible
for pleasure and movement. Over time, cocaine affects the brain’s
ability to recycle dopamine, requiring increasingly higher doses of the
drug to achieve the same effect, leading to a dangerous cycle of
addiction. Although injecting cocaine heightens one’s risk of contract-
ing HIV and hepatitis C through needle sharing, using cocaine
through any route of administration increases one’s likelihood of
engaging in high-risk sexual behaviors, which are also linked to the
transmission of both diseases [25]. 
3Methamphetamine (meth) is a synthetic
stimulant that can be smoked, snorted, or
dissolved and injected [26]. Like cocaine,
methamphetamine causes the brain to
release dopamine creating a sense of
pleasure after consumption. The use of
methamphetamine can also lead users to
experience paranoia, delusions, and hallu-
cinations. Long-term use may result in
emotional and cognitive problems,
extreme weight loss, dental problems
(“meth mouth”), and skin sores. When
injected, methamphetamine use increases
the individual’s risk for HIV and hepatitis
B and C through needle-sharing; howev-
er, the use of meth by any method may
heighten the probability for acquiring
such infectious diseases [26]. While a
pharmaceutical form of methampheta-
mine is available by prescription, meth is
usually manufactured illegally in clandes-
tine labs. In 2014, Indiana reported the
most clandestine meth lab seizures in the
country. Of the 9,338 clandestine labs
seized in the United States, 16% (1,471
incidents) occurred in Indiana [27].
However, the number of lab seizures in
Indiana has dropped since then to 943 in
2016 [28]. 
10-Year Trends in
Substance Use in Indiana
In the following section, we present find-
ings on the use and abuse of specific sub-
stances over a 10-year time span for
Indiana and the nation. The first part
examines substance use within the gen-
eral population; i.e., prevalence rate esti-
mates based on findings from the
National Survey on Drug Use and Health
(NSDUH) [29]. The second part discusses
drug use within the substance abuse
treatment population. It reflects the 10-
year trends of primary drugs (or drugs of
choice) reported at the time of treatment
admission; based on information from
the Treatment Episode Data System
(TEDS) [30].
Figure 1A. Percentage of Indiana residents ages 12 and older engaging in past-month use of alcohol, tobacco, and
 marijuana (NSDUH, 2006-2015)
Note: In 2015, SAMHSA modified the definition of binge drinking for women from “having five or more drinks on one
occasion” to “having four or more drinks.” As a result of these modifications, 2015 data on binge drinking cannot be
compared to NSDUH estimates from previous years.
Source: SAMHSA, 2017
Figure 1B. Percentage of U.S. residents ages 12 and older engaging in past-month use of alcohol, tobacco, and marijuana
(NSDUH, 2006-2015)
Note: In 2015, SAMHSA modified the definition of binge drinking for women from “having five or more drinks on one
occasion” to “having four or more drinks.” As a result of these modifications, 2015 data on binge drinking cannot be
compared to NSDUH estimates from previous years.
Source: SAMHSA, 2017
4Substance Use in the
General Population
(NSDUH)
Alcohol was the most widely used sub-
stance in Indiana. About half of all
Hoosiers ages 12 and older drank alcohol
in the past month and almost one-fourth
engaged in binge drinking. Tobacco con-
sumption was also high. Nearly one-third
of Indiana residents reported using tobac-
co (primarily cigarettes) in the past
month. Among illicit drugs, marijuana
was the drug most commonly used (see
Figure 1A) [29]. 
Over the past 10 years, prevalence rates
were similar in Indiana and the United
States for most substances, including
past-month use of alcohol and marijuana
as well as binge drinking. However,
Indiana exhibited higher rates of tobacco
use (see Figures 1A and 1B) [29].
Indiana’s high smoking prevalence, par-
ticularly among expectant mothers [4], led
the state to identify tobacco as one of its
substance abuse prevention priorities [31]. 
For substances that are less commonly
used in the general population, NSDUH
provides state-level estimates of past-year
use. This includes past-year prevalence
rates for cocaine, prescription pain reliev-
er (opioid analgesic), and, since 2014,
heroin abuse (state-level prevalence data
for methamphetamine are currently not
available). Among these three drug cate-
gories, prescription pain relievers were
the most frequently abused, followed by
cocaine, and heroin respectively (see
Figures 2A and 2B). Indiana and U.S.
rates were similar. [29]. 
Figure 2A. Percentage of Indiana residents ages 12 and older engaging in past-year use of cocaine, prescription pain
relievers, and heroin (NSDUH, 2006-2015)
Note: In 2015, SAMHSA completely revised the prescription drug module for pain relievers. As a result of these modifica-
tions, 2015 data on prescription pain reliever misuse cannot be compared to NSDUH estimates from previous years.
Also, state-level estimates for heroin use did not become available until 2014. 
Source: SAMHSA, 2017
Figure 2B. Percentage of U.S. residents ages 12 and older engaging in past-year use of cocaine, prescription pain reliev-
ers, and heroin (NSDUH, 2006-2015)
Note: In 2015, SAMHSA completely revised the prescription drug module for pain relievers. As a result of these modifica-
tions, 2015 data on prescription pain reliever misuse cannot be compared to NSDUH estimates from previous years.
Source: SAMHSA, 2017
5Substance Use in the
Treatment Population
(TEDS)
Both nationally and in Indiana, alcohol
has historically been the most widely used
substance and the primary reason for
people to seek treatment. A review of
TEDS data from 2005 through 2014
shows that in Indiana, alcohol and mari-
juana were the most frequently reported
substances, making up the bulk of treat-
ment admissions. The same trend held
true for the rest of the nation until 2012,
when heroin replaced marijuana as the
second most commonly reported drug of
choice. 
Among Indiana treatment admissions,
the popularity of other drugs also shifted
from 2005 through 2014. Use of cocaine,
initially the third most frequently reported
drug of choice in the state, decreased
from 12 percent to under 4 percent. At
the same time, treatment admissions for
heroin, prescription pain reliever, and
meth abuse rose substantially, reflecting
413%, 155%, and 66% increases respec-
tively since 2005. Although heroin use
was significantly lower among Indiana’s
treatment admissions compared to the
rest of the nation, the state has experi-
enced a steep rise in the proportion of
treatment episodes reporting heroin use.
Importantly, polysubstance use (i.e. the
use of two or more drugs) was reported in
over half of all treatment admissions. For
trend information on the primary drugs
reported at treatment admission from
2005 through 2014, see Figures 3A
(Indiana) and 3B (United States) [30]. 
Costs Attributable to
Substance Use in Indiana
The burden of substance abuse is consid-
erable, having a significant economic and
social impact on the state. Estimates from
2010, the most recent year for which data
were available, indicated that the costs of
alcohol use in Indiana exceeded $4.4 bil-
lion [32]. Furthermore, a more recent
Figure 3A. Indiana Percentage of Treatment Episodes by Primary Substance Reported at Admission (TEDS, 2005-2014)
Source: SAMHSA, 2014
Figure 3B. U.S. Percentage of Treatment Episodes by Primary Substance Reported at Admission (TEDS, 2005-2014)
Source: SAMHSA, 2014
report estimated that in Indiana tobacco use resulted in approximately $6.8 billion dollars
spent in 2014, in the form of health care costs, tax burdens, and lost productivity [33]. In the
same year, the costs attributable to drug overdose deaths were estimated at over $1.4 billion
[34]. Also, according to a state-by-state analysis published in 2015, opioid abuse is costing the
state over $650 million in health care costs [35].
In addition to its economic burden, substance abuse has significant societal implications,
including: 
1.   Overdose deaths
     In 2015, there were 1,236  overdose deaths in Indiana, more than double the fatalities
that occurred in 2005 (609 deaths) [36].
62.   Children exposed to meth labs
     In 2016, there were 153 Indiana children removed from homes
that contained a meth lab [28]. 
3.   Drug arrests
     In 2014, close to 23,000 arrests were made in Indiana for the
possession or sale of drugs, in addition to nearly 28,000 arrests
for DUI and public intoxication [37]. 
4.   Alcohol-related motor vehicle accidents
     In 2015, a total of 8,642 alcohol-related motor vehicle accidents
took place in Indiana, which resulted in 152 fatalities [38]. 
The economic and societal costs of substance abuse in Indiana sup-
port the need for further research and policy initiatives targeting pre-
vention and treatment for the consequences of alcohol, tobacco, and
other drug use. 
Risk and Protective Factors for Substance
Abuse
Most substance use occurs in early adulthood; therefore, addressing
risk and protective factors present in early life and adolescence can
influence future rates of substance abuse [39]. Risk factors for sub-
stance use include drug availability, neighborhood characteristics,
weak family relationships, family substance use, peer use, and mental
health problems [39-43]. The strongest predictive risk factor for sub-
stance use among youth was peer substance use [42, 43]. Conversely,
protective factors are those that mediate or moderate substance use.
Strong family relationships, neighborhood economic viability, low
childhood stress, restrictive laws, and excise taxes can all lower the
likelihood of substance use even in the face of risk factors [39, 42, 43].
Addressing these risk and protective factors would require tackling
many larger population concerns, but would likely result in benefits
to society beyond those associated with decreased substance use.
Because of the longitudinal nature of risk and protective factors, the
effect of interventions to reduce risk factors and enhance protective
factors may not be immediate and ongoing intervention and moni-
toring will be necessary to achieve maximum effectiveness [43]. 
Co-Occurring Mental Health and Substance
Use Disorders
Frequently called co-occurring disorder (COD) or dual diagnosis,
mental health and substance use disorders often occur together; i.e.,
people who have a mental health disorder are more likely to abuse
alcohol and/or illicit drugs and persons with a substance use disorder
are more likely to suffer from mental health conditions [44]. In 2015,
an estimated 3.3% of Americans experienced both some type of men-
tal illness and a substance use disorder; the prevalence rate for COD
was highest among young adults ages 18 to 25 [45]. 
Because mental health disorders are a risk factor for substance use
and vice versa, it is critical that we understand, monitor, and address
the relationship between these two conditions. Integrated treatment
for co-occurring disorders allows providers to address both disorders
together, saving time and resources and often creating better out-
comes than treatment for each disorder individually [44]. Current
efforts to address COD include improving care coordination between
primary care and mental health professionals, improving access to
services, and supporting vulnerable populations such as those in the
criminal justice system, individuals experiencing homelessness, and
veterans and their families [44]. 
Thoughts for Policymakers
Due to the numerous and often severe consequences linked to alco-
hol, tobacco, and other drugs, it is crucial that the state continues and
expands its efforts to prevent substance abuse and provide adequate
access to treatment. Indiana currently has various policies and pro-
grams in place that are designed to reduce the prevalence and inci-
dence of drug consumption, monitor patterns of abuse throughout
the state, and provide evidence-based programs to treat substance
use disorders and related health consequences. However, to keep
abreast of this ongoing issue, additional policies, strategies, and fund-
ing could prove beneficial in lessening the economic and social bur-
den to the state. To address this, our recommendations include:
1.   Expand access to substance abuse treatment services,
including medication-assisted treatment programs
     Adequate access to evidence-based treatment is crucial for
clients suffering from addictions. Medication-assisted
Treatment (MAT) incorporating methadone, buprenorphine, or
naltrexone in combination with counseling has been shown
effective in treating opioid use disorders [46, 47] and reducing
mortality, relapse, and costs compared to drug-free treatment
or no treatment [48]. Indiana currently has 14 accredited
Opioid Treatment Programs (OTPs) [49] and 321 physicians
who are licensed to provide buprenorphine to treat opioid
addiction [50]. However, a 2015 study found significant gaps
between the nation’s need for MAT and its capacity to provide
such services [51]. Indiana ranked as one of the worst states in
terms of high need and low MAT capacity. Although OTPs and
MAT programs have increased over the past 10 years, they
have not grown proportionally with the rise in opioid use and
dependence [51].
     Action steps to expand access to treatment could include:
• Encourage, train, and mentor eligible health care professionals
(physicians, nurse practitioners, and physician assistants) to
provide office-based MAT.
• Increase the number of OTPs and/or allow methadone mainte-
nance in community mental health centers to make it more
accessible to patients, especially in rural areas. 
72.   Incorporate a recovery-based framework 
     The recovery-oriented systems of care (ROSC) framework is a
relatively new effort supported by SAMHSA. ROSC uses a
chronic-care approach rather than an acute-care model for the
treatment of substance use disorders. Treatment is tailored to
individual needs and includes traditional SUD care in addition
to more comprehensive services such as employment training,
housing assistance, and childcare support. [52]. Several states,
including Arizona and Connecticut, have adopted state-wide
ROSC models. While many of the individual ROSC compo-
nents have been shown effective in addressing addictions,
comprehensive studies evaluating the full ROSC model are not
yet widely available [53]. 
     Action steps to incorporate a recovery-based framework could
include:
• Support a strong peer recovery workforce and allow Medicaid
billing for peer services.
• Increase funding for supportive services like job training, child
care, case management, family-inclusive services, and services
for vulnerable and underserved populations (e.g., LGBT, adoles-
cents, veterans, and those who have been incarcerated).
• Explore the use of regular post-discharge follow-ups for people
who leave treatment programs, especially those from vulnerable
and underserved populations.
• Advocate for elimination of punitive policies that terminate
services for people who relapse.
3.   Educate, train, and promote the use of naloxone among
first- and lay-responders 
     Naloxone is an opioid antagonist that is used to reverse the
effects of an opioid overdose [54]. Naloxone training programs
have been found effective in improving individuals’ ability to
accurately identify and address opioid overdoses [55-57] and
reducing opioid-related overdose deaths [58]. Current legisla-
tion and state efforts allow healthcare professionals, emergency
responders, and more recently, family members or friends of an
individual at risk of an opioid overdose to access and adminis-
ter the medication when necessary without legal implications
[59, 60], although the person revived can still face criminal
charges.
     Action steps to promote the use of naloxone could include:
• Train a broad range of social service and public health workers
to educate and promote the use of naloxone.
• Provide funds for social service and public health departments
to purchase and distribute naloxone kits.
• Advocate for elimination of punitive policies where individuals
revived from an overdose face criminal charges. 
4.   Prevent the transmission of HIV and hepatitis C in injec-
tion drug users
     Systematic reviews evaluating syringe exchange programs have
generally found compelling evidence that these programs are
effective in reducing transmission of HIV and hepatitis C [61-
64]. In light of the HIV epidemic in southern Indiana, the state
passed legislation allowing counties who have declared a public
health emergency from HIV or hepatitis C related to injection
drug use to operate syringe exchange programs [65]. At pres-
ent, Indiana has eight syringe exchange programs.  However,
this number may rise as the House passed a bill on January 31,
2017, allowing counties to establish syringe exchanges outside
of public health emergencies.  The bill is currently before the
Senate. 
     Action steps to prevent the transmission of HIV and hepatitis C
could include:
• Support laws that allow the establishment of syringe exchange
programs prior to counties experiencing a public health emer-
gency.
• Encourage syringe exchange programs to be “one-stop-shops;”
e.g., educating clients on how to prevent the transmission of
HIV and hepatitis C; connecting clients to treatment, if they
choose; and promoting the use of naloxone.  
• Advocate to decriminalize the possession of syringes.
5.   Implement effective youth prevention programs
     Most substance use occurs in young or emerging adulthood;
however, effective prevention initiatives early in life can influ-
ence future outcomes. A recent comprehensive review of ado-
lescent substance use prevention efforts found that school-
based interventions were the most effective across substances
while the effect of family-centered interventions varied by sub-
stance [66].
     Many evidence-based curricula exist, but school adoption and
effective implementation of such curricula is lacking [67-70].
Recent teacher or substance use prevention instructor training
and use of interactive teaching strategies may help improve the
effectiveness of evidence-based programs. Selecting and
encouraging personality-specific, interactive, evidence-based
curricula as well as school participation in programs such as
Drug-Free Communities Support Program and Safe
Schools/Healthy Students may be useful tools for preventing
youth substance use in Indiana. 
     Action steps for effective youth prevention could include:
8• Allocate prevention funding to favor evidence- and school-
based programming, especially programs that support positive
peer relationships and social competence/social influence
approaches.
• Encourage schools to offer evidence-based family programming
(e.g., Strengthening Families) to supplement classroom pro-
grams.
6.   Monitor substance abuse and consequences 
     State-level tracking systems that collect information on indica-
tors of substance abuse are essential tools for monitoring the
opioid epidemic and other drug-related issues in Indiana. One
of these information systems is INSPECT, Indiana’s prescrip-
tion drug monitoring program. Evidence suggests that pre-
scription drug monitoring programs are effective in tracking
prescribing and dispensing patterns of controlled substances
[71] and reducing the rate increase of opioid use and misuse
[72]. Surveillance and/or advisory bodies with access to a wide
variety of relevant data across agencies and organizations are
vital in compiling, analyzing, and interpreting the information. 
     Action steps for monitoring substance abuse could include:
• Allow linkage of INSPECT to other databases such as electronic
health records.  
• Encourage the consistent and accurate collection of data
statewide, especially at sub-state (e.g., county) levels, across
agencies and organizations
• Advocate for additional funding for statewide surveys to be
administered in a manner that allows for county-level estimates
• Require coroners to report when a drug overdose caused or
contributed to a death and have a comprehensive drug panel
performed to indicate on the death certificate the specific
drug(s) involved.
• Set up an early warning system for the state, similar to
SAMHSA’s now defunct Drug Abuse Warning Network
(DAWN) to track emergency department visits caused by drug
abuse in order to identify the drugs being abused, determine
patterns and changing/emerging trends in specific areas of the
state.
• Require complete reporting of alcohol- and drug-related arrests
by law enforcement and develop a unified reporting system
across all law enforcement agencies.
Conclusion 
Over the past 10 years, alcohol and tobacco have been the most
widely used substances in Indiana. Marijuana, though still illegal in
Indiana, has gained much more public acceptance due to the chang-
ing landscape of state marijuana laws. As of 2016, more than half of
all U.S. states have legalized marijuana for medical and/or recreation-
al purposes. The opioid epidemic involving both prescription pain
relievers and heroin has impacted Indiana tremendously, with sub-
stantial increases in substance abuse treatment admissions and over-
dose deaths attributable to these drugs. 
Indiana has established many efforts to prevent and reduce substance
abuse in the state, but these programs and policies should continue
to be evaluated and revised as trends in substance use change. 
9References
1.   Center for Behavioral Health Statistics and Quality, Behavioral Health Trends in the United States: Results from the 2014 National Survey on
Drug Use and Health, in HHS Publication No. SMA 15-4927 NSDUH Series H-50. 2015, Substance Abuse and Mental Health Services
Administration,: Rockville, MD.
2.   Centers for Disease Control and Prevention, Drug Overdose Death Data. 2016.
3.   United Health Foundation, America’s Health Rankings Annual Report, U.H. Foundation, Editor. 2016, United Health Foundation.
4.   Curtin, S.C. and T.J. Matthews, Smoking Prevalence and Cessation Before and During Pregnancy: Data From the Birth Certificate, 2014.Natl Vital
Stat Rep, 2016. 65(1): p. 1-14.
5.   U.S. Department of Health and Human Services and Office of Disease Prevention and Health Promotion, Healthy People 2010 midcourse
review: Focus area 26, substance abuse 2006, HHS: Washington.
6.   National Institute on Drug Abuse. Medical Consequences of Drug Abuse. 2012; Available from: 
https://www.drugabuse.gov/related-topics/medical-consequences-drug-abuse.
7.   National Institute on Drug Abuse. Trends & Statistics. 2015; Available from: 
https://www.drugabuse.gov/related-topics/trends-statistics#costs.
8.   Centers for Disease Control and Prevention. Alcohol and Public Health. 2016; Available from: https://www.cdc.gov/alcohol/faqs.htm.
9.   National Institutes of Health. Alcohol’s Effects on the Body. n.d.; Available from: 
https://www.niaaa.nih.gov/alcohol-health/alcohols-effects-body.
10.National Institute on Drug Abuse. Drug Facts: Cigarettes and Other Tobacco Products. 2016; Available from: 
https://www.drugabuse.gov/publications/drugfacts/cigarettes-other-tobacco-products.
11.U.S. Department of Health and Human Services, The health consequences of smoking--50 years of progress : a report of the Surgeon General. 2014,
Atlanta: Department of Health and Human Services.
12.Centers for Disease Control and Prevention. Reproductive Health: Tobacco Use and Pregnancy. 2016; Available from:
https://www.cdc.gov/reproductivehealth/maternalinfanthealth/tobaccousepregnancy/.
13.National Institute on Drug Abuse. Drug Facts: Marijuana. 2016; Available from: http://www.drugabuse.gov/publications/drugfacts/marijuana.
14.Medina, K.L., et al., Depressive symptoms in adolescents: associations with white matter volume and marijuana use. J Child Psychol Psychiatry,
2007. 48(6): p. 592-600.
15.Green, B.E. and C. Ritter, Marijuana use and depression. J Health Soc Behav, 2000. 41(1): p. 40-9.
16.Chen, C.Y., F.A. Wagner, and J.C. Anthony, Marijuana use and the risk of Major Depressive Episode. Epidemiological evidence from the United
States National Comorbidity Survey. Soc Psychiatry Psychiatr Epidemiol, 2002. 37(5): p. 199-206.
17.Harder, V.S., A.R. Morral, and J. Arkes, Marijuana use and depression among adults: Testing for causal associations. Addiction, 2006. 101(10): p.
1463-72.
18.Denson, T.F. and M. Earleywine, Decreased depression in marijuana users. Addict Behav, 2006. 31(4): p. 738-42.
19.National Conference of State Legislatures. State Medical Marijuana Laws. 2017; Available from: 
http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx#Table2.
20.Steinmetz, K., These States Just Legalized Marijuana, in Time. 2016.
21.National Institute on Drug Abuse. Misuse of Prescription Drugs. 2016; Available from: 
https://www.drugabuse.gov/publications/research-reports/misuse-prescription-drugs/summary.
22.National Institute on Drug Abuse. Drug Facts: Prescription and Over-the-Counter Medications. 2015; Available from:
https://www.drugabuse.gov/publications/drugfacts/prescription-over-counter-medications.
23.National Institute on Drug Abuse. Prescription Opioids and Heroin. 2015; Available from: 
https://www.drugabuse.gov/publications/research-reports/relationship-between-prescription-drug-abuse-heroin-use/introduction.
10
24.National Institute on Drug Abuse. Drug Facts: Heroin. 2017; Available from: https://www.drugabuse.gov/publications/drugfacts/heroin.
25.National Institute on Drug Abuse, Drug Facts: Cocaine. 2016.
26.National Institute on Drug Abuse, Drug Facts: Methamphetamine. 2017.
27.U.S. Drug Enforcement Administration, Methamphetamine Lab Incidents, 2004-2014. 2014.
28. Indiana State Police and Methamphetamine Suppression Section, Indiana meth lab statistics, 2015, Data received on January 14, from
Sergeant Katrina Smith, Editor. 2015.
29.Substance Abuse and Mental Health Services Administration and Center for Behavioral Health Statistics and Quality. National Survey on
Drug Use and Health. 2017; Available from: https://www.samhsa.gov/data/population-data-nsduh  
30.Substance Abuse and Mental Health Services Administration and Center for Behavioral Health Statistics and Quality. Treatment Episode
Data Set -- Admissions (TEDS-A). 2017; Available from: http://wwwdasis.samhsa.gov/dasis2/teds.htm 
31. Indiana State Epidemiological Outcomes Workgroup, Indiana Strategic Substance Abuse Prevention & Mental Health Promotion Priorities. 2016,
Center for Health Policy, Indiana University Richard M. Fairbanks School of Public Health.
32.Sacks, J.J., et al., 2010 National and State Costs of Excessive Alcohol Consumption. Am J Prev Med, 2015. 49(5): p. e73-9.
33. IU Richard M. Fairbanks School of Public Health, Report on the Tobacco Epidemic in Marion County and Indiana. 2016.
34.Duwve, J., et al., Report on the Toll of Opioid Use in Indiana and Marion County. 2016.
35.Matrix Global Advisors, L., Health Care Costs from Opioid Abuse: A State-by-State Analysis. 2015.
36. Indiana State Department of Health, Epidemiology Resource Center, and Data Analysis Team, Drug overdose deaths involving opioid pain
relievers and other drugs by death year, Indiana, 1999-2015. 2017: Indianapolis, IN.
37.Federal Bureau of Investigation, Uniform Crime Reporting (UCR) program data: County-level detailed arrest and offense data, 2014. 2014,  
Inter-university Consortium for Political and Social Research: Ann Arbor, MI.
38. Indiana State Police, Automated Reporting Information Exchange System (ARIES), Vehicle Crash Records System, 2015, Data received November
28, from the Center for Criminal Justice Research, Public Policy Institute, School of Public and Environmental Affairs, Indiana University–
Purdue University Indianapolis., Editor. 2015.
39. Stone, A.L., et al., Review of risk and protective factors of substance use and problem use in emerging adulthood. Addict Behav, 2012. 37(7): p. 747-75.
40.Clark, T.T. and T. Washington, Substance Use Risk and Protective Factors, in Encyclopedia of Adolescence. 2011, Springer New York. p. 2910-
2919.
41.Swendsen, J., et al., Mental disorders as risk factors for substance use, abuse and dependence: results from the 10-year follow-up of the National
Comorbidity Survey. Addiction, 2010. 105(6): p. 1117-28.
42.Swadi, H., Individual risk factors for adolescent substance use. Drug Alcohol Depend, 1999. 55(3): p. 209-24.
43.Hawkins, J.D., R.F. Catalano, and J.Y. Miller, Risk and protective factors for alcohol and other drug problems in adolescence and early adulthood:
implications for substance abuse prevention. Psychol Bull, 1992. 112(1): p. 64-105.
44.Substance Abuse and Mental Health Services Administration, Co-occurring Disorders. 2016.
45.Substance Abuse and Mental Health Services Administration, National Survey on Drug Use and Health (tables 8.27B and 9.14B). 2015.
46.Marsch, L.A., The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis.
Addiction, 1998. 93(4): p. 515-32.
47.Substance Abuse and Mental Health Services Administration. Medication and Counseling Treatment. 2015; Available from:
https://www.samhsa.gov/medication-assisted-treatment/treatment.
48.Clark, R.E., et al., The evidence doesn't justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine. Health Aff
(Millwood), 2011. 30(8): p. 1425-33.
49.Substance Abuse and Mental Health Services Administration. Opioid Treatment Program Directory. [cited 2017 March 1, 2017]; Available
from: http://dpt2.samhsa.gov/treatment/directory.aspx.
11
50.Substance Abuse and Mental Health Services Administration. Buprenorphine Treatment Physician Locator. 2017  [cited 2017; Available from:
https://www.samhsa.gov/medication-assisted-treatment/physician-program-data/treatment-physician-locator.
51. Jones, C.M., et al., National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment. Am J Public Health, 2015.
105(8): p. e55-63.
52.Kaplan, L., The role of recovery support services in Recovery-Oriented Systems of Care. 2008, Center for Substance Abuse Services, Substance
Abuse and Mental Health Services Administration: Rockville, MD.
53.Laudet, A.B. and K. Humphreys, Promoting recovery in an evolving policy context: what do we know and what do we need to know about recovery
support services? J Subst Abuse Treat, 2013. 45(1): p. 126-33.
54.Substance Abuse and Mental Health Services Administration. Naloxone. 2016; Available from: 
https://www.samhsa.gov/medication-assisted-treatment/treatment/naloxone.
55.Behar, E., et al., Brief overdose education is sufficient for naloxone distribution to opioid users. Drug and Alcohol Dependence, 2015. 148: p. 209-
212.
56. Jones, J.D., et al., Brief overdose education can significantly increase accurate recognition of opioid overdose among heroin users. International
Journal of Drug Policy, 2014. 25(1): p. 166-170.
57.Lott, D.C. and J. Rhodes, Opioid overdose and naloxone education in a substance use disorder treatment program. American Journal on
Addictions, 2016. 25(3): p. 221-226.
58.Walley, A.Y., et al., Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted
time series analysis. BMJ, 2013. 346: p. f174.
59. Indiana Code §16-31-3-23.5.
60. Indiana Code §16-42-27-2.
61.Strathdee, S.A. and D. Vlahov, The effectiveness of needle exchange programs: A review of the science and policy. AIDScience, 2001. 1(16): p. 1-33.
62.Gibson, D.R., N.M. Flynn, and D. Perales, Effectiveness of syringe exchange programs in reducing HIV risk behavior and HIV seroconversion among
injecting drug users. AIDS, 2001. 15(11): p. 1329-41.
63.Wodak, A. and A. Cooney, Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international
evidence. Substance use & misuse, 2006. 41(6-7): p. 777-813.
64.Abdul-Quader, A.S., et al., Effectiveness of structural-level needle/syringe programs to reduce HCV and HIV infection among people who inject drugs:
a systematic review. AIDS and Behavior, 2013. 17(9): p. 2878-2892.
65. Indiana Code §16-41-7.5.
66.Das, J.K., et al., Interventions for Adolescent Substance Abuse: An Overview of Systematic Reviews. J Adolesc Health, 2016. 59(4S): p. S61-S75.
67.Gottfredson, D.C. and G.D. Gottfredson, Quality of school-based prevention programs: Results from a national survey. Journal of Research in
Crime and Delinquency, 2002. 39(1): p. 3-35.
68.Ringwalt, C.L., et al., Factors associated with fidelity to substance use prevention curriculum guides in the nation's middle schools. Health Educ
Behav, 2003. 30(3): p. 375-91.
69.Ennett, S.T., et al., A comparison of current practice in school-based substance use prevention programs with meta-analysis findings. Prev Sci, 2003.
4(1): p. 1-14.
70.Ringwalt, C., et al., The Prevalence of Effective Substance Use Prevention Curricula in the Nation's High Schools. Journal of Primary Prevention,
2008. 29(6): p. 479-488.
71.Clark, T., et al., Prescription drug monitoring programs: an assessment of the evidence for best practices. Report: September, 2012. 20.
72.Reifler, L.M., et al., Do Prescription Monitoring Programs Impact State Trends in Opioid Abuse/Misuse? Pain Medicine, 2012. 13(3): p. 434-442.
The mission of the Center for Health Policy is to conduct research on critical health-related issues and translate data into evidence-based poli-
cy recommendations to improve community health. The CHP faculty and staff collaborate with public and private partners to conduct quality
data driven program evaluation and applied research analysis on relevant public health issues. The Center serves as a bridge between academic
health researchers and federal, state and local government as well as healthcare and community organizations.
Authors: Casey Balio, BA, and Marion Greene, MPH, PhD(c)
Please direct all correspondence and questions to: Marion Greene, MPH, PhD(c), Center for Health Policy, IU Richard M Fairbanks School of
Public Health at IUPUI, 1050 Wishard Blvd, RS5163, Indianapolis, IN 46202; Email: msgreene@iu.edu; Phone: (317)278-3247.
